TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31808786
Drug: Informational treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Informational treatment about opioids
Study: 30714749
Drug: Group interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Study: 28345762
Drug: Low carbohydrate
Normalized name: Low carbohydrate beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low carbohydrate diet (LCD) (≤50 g/d)
Study: 28345762
Drug: High carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High carbohydrate diet (HCD) (≥250 g/d)
Study: 24151390
Drug: Anisodamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anisodamine (10 mg every 8 hours for 2 weeks)
Study: 17243700
Drug: Tangerine sauce
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangerine sauce (150 g containing 15 g of corn oil, 13 mg of lycopene)
Study: 17243700
Drug: High-beta-carotene sauce
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-beta-carotene sauce (150 g containing 15 g of corn oil, 17 mg of total beta-carotene, 4 mg of lycopene)
Study: 14722172
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 2 micro g kg(‐1)
Study: 14722172
Drug: Caudal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caudal clonidine 2 micro g kg(‐1)
Study: 3287973
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefotetan as a single prophylactic dose
Study: 3287973
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g cefotetan as a single dose
Study: 3287973
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g cefoxitin every 6 hours for a maximum of 4 doses
Study: 24244339
Drug: Ad35.CS.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35.CS.01 vaccine (10^9, 10^10, 5X10^10, 10^11 vp) administered on days 0, 28, and 84
Study: 24244339
Drug: Ad35.CS.01 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad35.CS.01 vaccine
Study: 14748475
Drug: Cyclical etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclical etidronate treatment (200 mg/day for 2 weeks per 3 months)
Study: 14748475
Drug: Alendronate treatment
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate treatment (5 mg/day)
Study: 8642881
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment using a bilevel positive airway pressure (PAP) device set to deliver an inspiratory pressure of 0 cm H2O and a minimal expiratory pressure of 2 cm H2O.
Study: 8642881
Drug: Nocturnal nasal
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal nasal ventilation (NNV) and Sham treatment
Study: 1505287
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg at night (2200 hr)
Study: 1505287
Drug: ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranitidine 150 mg three times a day (1800, 0800 and 1200 hr)
Study: 6098223
Drug: Hand lotion
Normalized name: CVS Intense Dry Skin Therapy Hand Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand lotion containing 2% glutaric acid
Study: 9822501
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 as a 0.5-mg intracervical gel (Prepidil) with immediate oxytocin
Study: 9822501
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 as a 10-mg controlled-release vaginal insert (Cervidil) with delayed oxytocin
Study: 7927956
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg plus Hydrochlorothiazide 12.5 mg
Study: 2913132
Drug: Albuterol repeat‐action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol repeat‐action tablets with a high fat content breakfast
Study: 2913132
Drug: Albuterol repeat‐action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol repeat‐action tablets without food
Study: 163848
Drug: Polymyxin aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin aerosol (2.5 mg/kg body wt/day in six divided doses)
Study: 28537001
Drug: tiotropium/olodaterol fixed‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiotropium/olodaterol fixed‐dose combination (FDC)
Study: 27503566
Drug: TRPV1 agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRPV1 agonist (capsaicin 1 × 10(−5) M)
Study: 25171815
Drug: Carbohydrate/Electrolyte Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate/Electrolyte Solution (CES)
Study: 17150023
Drug: ID-KLH vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID-KLH vaccine plus granulocyte-macrophage colony-stimulating factor
Study: 15116260
Drug: Pravastatin (HMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (HMG CoA reductase inhibitor)
Study: 11603956
Drug: Copper dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper dose of 2 mg Cu/L
Study: 11603956
Drug: Copper dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper dose of 4 mg Cu/L
Study: 11603956
Drug: Copper dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper dose of 6 mg Cu/L
Study: 11603956
Drug: Copper dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper dose of 8 mg Cu/L
Study: 11603956
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 mg Cu/L)
Study: 9557622
Drug: Influenza virus
Normalized name: Influenza virus Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza virus vaccine (1996-1997)
Study: 9557622
Drug: B/T lymphocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: B/T lymphocyte ratio during chemotherapy
Study: 11271343
Drug: Long-term steroid
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term steroid therapy (0.1 mg/kg per day)
Study: 2651949
Drug: Furosemide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (200 mg IV every 6 hours for 4 days)
Study: 2651949
Drug: Furosemide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (200 mg IV every 6 hours) with dopamine (1 microgram/kg/min for 4 days)
Study: 1124717
Drug: Propranolol (increasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (increasing doses)
Study: 23639514
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (DEX, 0.5 μg/kg; n = 18)
Study: 21286241
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg nightly (n = 17)
Study: 17061999
Drug: FTY720 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 5.0 mg plus reduced-dose cyclosporine (RDC)
Study: 17061999
Drug: FTY720 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 5.0 mg
Study: 15055565
Drug: Olopatadine 0.2%
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine 0.2% solution
Study: 8833678
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment approaches
Study: 2414023
Drug: Cisplatinum and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatinum and Bleomycin (combined treatment)
Study: 29158011
Drug: Extended intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended intermittent letrozole (2.5 mg/day orally for 9 months followed by a 3-month break in years 1-4 and then 2.5 mg/day during all 12 months of year 5)
Study: 29158011
Drug: Continuous letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous letrozole (2.5 mg/day orally for 5 years)
Study: 28453454
Drug: Intra-articular hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronate and tramadol injection
Study: 28453454
Drug: Intra-articular hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronate injection alone
Study: 18328348
Drug: rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rosiglitazone (RSG) 4 mg/d (increased to 8 mg/d after 6 months) plus glibenclamide
Study: 17139601
Drug: Prostanoids, endothelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostanoids, endothelin receptor antagonists, or phosphodiesterase 5 inhibitors
Study: 17139601
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of underlying disease
Study: 14971794
Drug: Phentolamine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine 0.2 mg kg(‐1) i.v.
Study: 31987228
Drug: S. officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. officinalis extract (330 mg daily for 8 weeks)
Study: 24177170
Drug: No pre‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre‐treatment (NS, control) with DMG LUXACORE Smartmix Dual
Study: 19352324
Drug: VEGF gene
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF gene therapy (2,000 microg of VEGF plasmid DNA)
Study: 19352324
Drug: VEGF gene
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF gene therapy
Study: 17445644
Drug: Prophylactic low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic low-molecular-weight heparin for 1 week (Group 2)
Study: 17445644
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin for 1 week (Group 3)
Study: 17445644
Drug: Conventional heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional heparin (Group 3)
Study: 15878544
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) followed by acenocoumarol
Study: 26648706
Drug: Fluticasone propionate/formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/formoterol (two doses)
Study: 23289773
Drug: Psychological preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological preoperative program (group 1) including psychological preparation activities and psychologist's support during all phases of the operatory iter.
Study: 17530622
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy intervention
Study: 12614418
Drug: Three treatments
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three treatments with cooled 40‐ms alexandrite laser (fluences of 16 to 24 J/cm2)
Study: 12614418
Drug: Two treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two treatments with cooled 40‐ms alexandrite laser (fluences of 16 to 24 J/cm2)
Study: 12614418
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment with cooled 40‐ms alexandrite laser (fluences of 16 to 24 J/cm2)
Study: 1998281
Drug: Questran Light
Normalized name: Questran Light
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Questran Light (4 g of cholestyramine in 5 g of powder per pack)
Study: 1998281
Drug: Questran (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Questran (4 g of cholestyramine in 9 g of powder per pack)
Study: 31075171
Drug: Artesunate therapy
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate therapy
Study: 24254301
Drug: Functional beverage
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional beverage (FB) consumed 187 mL acutely and twice a day for 15 days chronically
Study: 20852059
Drug: Biventricular pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biventricular pacing with peri-infarct LV lead placement (cardiac resynchronization therapy [CRT]-D)
Study: 9125457
Drug: Linear acceleration
Normalized name: Aspalathus linearis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linear acceleration steps of 0.05 g, 0.1 g, or 0.24 g amplitude
Study: 2576366
Drug: Picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picumast dihydrochloride (2 mg twice daily orally)
Study: 2576366
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily orally)
Study: 26627982
Drug: Corticosteroids (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (IV or PO administration totaling more than 20 mg methylprednisolone equivalents during one calendar day)
Study: 16945121
Drug: Silodosin 4
Normalized name: silodosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silodosin 4 mg twice daily (severe symptoms subgroup)
Study: 27166233
Drug: Zolpidem CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem CR 12.5 mg
Study: 18566972
Drug: i.v. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. placebo administration with glucose expectation
Study: 15772863
Drug: 19-mg caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 19-mg caffeine and 250-mg theobromine
Study: 7478687
Drug: Sterile Water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile Water Injections (SWI)
Study: 7478687
Drug: Saline Injections
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline Injections (PSI)
Study: 28389217
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of octopamine
Study: 21788663
Drug: Idebenone 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 900 mg/day
Study: 10690882
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE; 0.625 mg daily)
Study: 10690882
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg daily) plus CEE (0.625 mg daily)
Study: 9350365
Drug: Thiamylal 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamylal 5 mg.kg-1 with inhalation of 100% oxygen (Group C)
Study: 1443509
Drug: Racemic ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racemic ketamine 2 mg/kg bw
Study: 1443509
Drug: S-(+)-ketamine 1
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 1 mg/kg bw
Study: 1443509
Drug: S-(+)-ketamine 1
Normalized name: (S)-(-)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-(+)-ketamine 1 mg/kg bw with midazolam 0.1 mg/kg i.v.
Study: 2422103
Drug: Insulin plus
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin plus aprotinin (10,000 KIU for every 10 U.I. insulin)
Study: 2422103
Drug: Insulin by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin by itself
Study: 26707592
Drug: Fostamatinib 200
Normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostamatinib 200 mg BID
Study: 26707592
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg BID
Study: 22196968
Drug: 1-year treatment:
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-year treatment: induction: IFN alfa-2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks, maintenance: IFN alfa-2b, 10 MU (flat dose), SC, 3 days/week for 12 months (n = 285)
Study: 22196968
Drug: 2 years
Normalized name: Childrens Panadol 5 - 12 Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 years of same treatment as Arm B (n = 285)
Study: 15316947
Drug: Two-step off-drug
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step off-drug QT correction analysis
Study: 15316947
Drug: One-step off-
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step off- and on-drug QT analysis
Study: 11139800
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin 5000 units subcutaneously every 8 hours
Study: 11139800
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg subcutaneously daily
Study: 8396082
Drug: Comparator agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator agents (co-amoxiclav, amoxycillin, penicillin V, erythromycin, dicloxacillin, flucloxacillin)
Study: 29924907
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and oral tamoxifen (40 mg/day for 20 days)
Study: 29924907
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and topical tamoxifen (0.1% tamoxifen citrate for 20 days)
Study: 29924907
Drug: Standard meglumine
Normalized name: Meglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard meglumine antimoniate (20 mg/kg/day for 20 days)
Study: 27084921
Drug: Isavuconazole (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (20, 40, or 60 mg/kg every 24 h after a 90 mg/kg loading dose for 12 days)
Study: 27084921
Drug: Isavuconazole (clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (clinical dosing regimen)
Study: 25420830
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid therapy (Group B)
Study: 9574332
Drug: Automatic pen
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic pen for subcutaneous injections of low molecular heparin
Study: 8365195
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg beta-carotene and 25,000 IU vitamin A as retinyl palmitate (intervention)
Study: 18840077
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg single dose of orally administered fluconazole
Study: 18840077
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of orally administered fluconazole once per day for 2 weeks
Study: 11379466
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg daily for 10 days
Study: 29514317
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (Nicoderm 14 mg)
Study: 29514317
Drug: Nicotine spray
Normalized name: nicotine Metered Dose Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine spray (Nicotrol, 2 × 1 mg/trial)
Study: 29514317
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch plus placebo spray
Study: 25790943
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg slow‐release isosorbide‐5-mononitrate (ISMN)
Study: 16279258
Drug: Lung-volume-reduction surgery
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung-volume-reduction surgery (LVRS) plus medical treatment
Study: 9329348
Drug: 35 mg
Normalized name: papain 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 mg hydrocortisone
Study: 3525386
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir plus 5% acyclovir cream
Study: 3525386
Drug: Oral acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral acyclovir plus matching placebo cream
Study: 28566441
Drug: Weekly Jintrolong
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Jintrolong (0.2 mg/kg/week)
Study: 28566441
Drug: Daily rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rhGH (0.25 mg/kg/week)
Study: 23474384
Drug: Preference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference group (varied treatments)
Study: 21937848
Drug: Astaxanthin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin supplementation (3 mg/day) for 4 or 12 weeks
Study: 21937848
Drug: Astaxanthin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin supplementation (1 mg/day)
Study: 19430742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two antihistamines (levocetirizine 10 mg/fexofenadine 360 mg)
Study: 19430742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three antihistamines (levocetirizine 10 mg/fexofenadine 360 mg/azelastine 4 mg)
Study: 19430742
Drug: High dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosage desloratadine (20 mg)
Study: 16377455
Drug: Parallel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel treatment
Study: 9564642
Drug: GnRH‐a (buserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐a (buserelin acetate, 600 μg/d for six weeks) plus hMG (conventional doses for 14 cycles)
Study: 9564642
Drug: Low-dose hMG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hMG (for 17 cycles)
Study: 782146
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage heparin
Study: 31623498
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg/d) following ROCKET AF criteria
Study: 31623498
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg/d) following J-ROCKET AF criteria
Study: 31623498
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg/d) following ROCKET AF criteria